Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

• Status: Recruiting
• Trial end date: 2024-12-31

Summary

This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to treatment or that has come back. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, including vincristine, cyclophosphamide, dexamethasone, rituximab, methotrexate, and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with low-intensity chemotherapy may work better in treating patient with B- or T-cell acute lymphoblastic leukemia.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: 6-methoxypurine arabinoside; Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Asparaginase; BB 1101; Cortisone; Cortisone acetate; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone acetate; Immunoglobulins; Methotrexate; Pegaspargase; Prednisone; Rituximab; Venetoclax; Vincristine